Patent: 8,231,876
✉ Email this page to a colleague
Summary for Patent: 8,231,876
Title: | Purified antibody composition |
Abstract: | The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. |
Inventor(s): | Wan; Min M. (Worcester, MA), Avgerinos; George (Sudbury, MA), Zarbis-Papastoitsis; Gregory (Watertown, MA) |
Assignee: | Abbott Biotechnology Ltd. (Hamilton, BM) |
Application Number: | 12/882,601 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,231,876 |
Patent Claims: | see list of patent claims |
Details for Patent 8,231,876
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | December 31, 2002 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | February 21, 2008 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | April 24, 2013 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | September 23, 2014 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | November 23, 2015 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | March 09, 2016 | ⤷ Sign Up | 2026-04-05 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | October 17, 2016 | ⤷ Sign Up | 2026-04-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |